Surgical Treatment of Peri-implantitis With Adjunctive Application of Platelet Rich Fibrin (PRF)
Launched by UNIVERSITY OF BERN · Nov 5, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new treatment approach for a condition called peri-implantitis, which is an infection that affects the area around dental implants. The study aims to see if adding a special substance called platelet-rich fibrin (PRF) to a standard surgical treatment can help improve healing and bone regeneration in patients with this condition. PRF is a concentrate made from your own blood that contains growth factors, which are substances that help promote healing. The researchers want to find out if using PRF along with a specific cleaning method for the implants leads to better outcomes than just the cleaning method alone.
To participate in this trial, individuals should be between the ages of 65 and 74 and have one or more implants showing signs of infection, such as deep pockets around the implant and bone loss visible on X-rays. They should also have good oral hygiene. However, those with certain medical conditions, like diabetes or chronic inflammatory diseases, and pregnant or nursing women are not eligible. Participants will undergo the treatment and then be monitored for 12 months to check how well the area around their implants heals. This trial will help determine if PRF can be a useful addition to current treatments for peri-implantitis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. One or more peri-implant sites with PPD ≧ 5 mm combined with BOP/suppuration and
- • 2. Peri-implant marginal bone loss, defined as a crater like defect ≧ 3 mm as assessed from intraoral radiographs
- • 3. Good oral hygiene i.e. a plaque index \<20%
- • 4. Written informed consent
- Exclusion Criteria:
- • 1. History of chronic inflammatory disease
- • 2. Severe systemic diseases
- • 3. Medically confirmed diagnosis of diabetes mellitus
- • 4. Anti-inflammatory prescription including prednisone
- • 5. Smoking \> 5 cigarettes
- • 6. Pregnant or lactating women
- • 7. \< 18 years of age
About University Of Bern
The University of Bern, a leading research institution in Switzerland, is dedicated to advancing medical knowledge and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, the university fosters an environment where scientific inquiry and clinical application intersect. Its commitment to ethical standards and patient safety ensures that all trials are conducted with the highest integrity, striving to contribute valuable insights to the global medical community. The University of Bern actively engages in diverse therapeutic areas, aiming to translate research findings into tangible health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Giovanni Salvi, MD
Principal Investigator
University of Bern
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported